Unfavorable efficacy of pembrolizumab for advanced extramammary Paget's disease with high tumor mutation burden after failure of taxane‐based regimens

The Journal of DermatologyEarly View LETTER TO THE EDITOR Unfavorable efficacy of pembrolizumab for advanced extramammary Paget's disease with high tumor mutation burden after failure of taxane-based regimens Shigeru Koizumi, Corresponding Author Shigeru Koizumi [email protected] orcid.org/0000-0002-7213-4708 Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan Department of Dermatology, Chiba University, Chiba, Japan Correspondence Shigeru Koizumi, Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298 Japan. Email: [email protected]Search for more papers by this authorReiichi Doi, Reiichi Doi Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorUrara Aitake, Urara Aitake Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorXiaofeng Lei, Xiaofeng Lei Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorTeruaki Izumi, Teruaki Izumi Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorTatsuhiko Mori, Tatsuhiko Mori Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorNaoko Shojiguchi, Naoko Shojiguchi Department of Pathology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorTomonori Kawasaki, Tomonori Kawasaki Department of Pathology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorTakashi Inozume, Takashi Inozume orcid.org/0000-0001-7054-1863 Department of Dermatology, Chiba University, Chiba, JapanSearch for more papers by this authorAkiko Kishi, Akiko Kishi Department of Dermatology, Toranomon Hospital, Tokyo, JapanSearch for more papers by this author Shigeru Koizumi, Corresponding Author Shigeru Koizumi [email protected] orcid.org/0000-0002-7213-4708 Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan Department of Dermatology, Chiba University, Chiba, Japan Correspondence Shigeru Koizumi, Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298 Japan. Email: [email protected]Search for more papers by this authorReiichi Doi, Reiichi Doi Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorUrara Aitake, Urara Aitake Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorXiaofeng Lei, Xiaofeng Lei Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorTeruaki Izumi, Teruaki Izumi Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorTatsuhiko Mori, Tatsuhiko Mori Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorNaoko Shojiguchi, Naoko Shojiguchi Department of Pathology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorTomonori Kawasaki, Tomonori Kawasaki Department of Pathology, Saitama Medical University International Medical Center, Saitama, JapanSearch for more papers by this authorTakashi Inozume, Takashi Inozume orcid.org/0000-0001-7054-1863 Department of Dermatology, Chiba University, Chiba, JapanSearch for more papers by this authorAkiko Kishi, Akiko Kishi Department of Dermatology, Toranomon Hospital, Tokyo, JapanSearch for more papers by this author First published: 12 January 2024 https://doi.org/10.1111/1346-8138.17101Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Kibbi N, Owen JL, Worley B, Wang JX, Harikumar V, Downing MB, et al. Evidence-based clinical practice guidelines for extramammary Paget disease. JAMA Oncol. 2022; 8: 618–628. 10.1001/jamaoncol.2021.7148 PubMedWeb of Science®Google Scholar 2Miyashita A, Fukushima S, Yoshino K, Kato H, Yamazaki N, Kawashima S, et al. Real-world efficacy of chemotherapy in patients with advanced extramammary Paget's disease: a retrospective, multicenter study of 204 Japanese patients. J Clin Oncol. 2023; 41:e21579. 10.1200/JCO.2023.41.16_suppl.e21579 Web of Science®Google Scholar 3Kashiwada-Nakamura K, Myangat TM, Kajihara I, Kusaba Y, Tanaka K, Sakamoto R, et al. Absence of microsatellite instability in extramammary Paget's disease. Skin Health Dis. 2021; 1:e37. 10.1002/ski2.37 CASPubMedGoogle Scholar 4Nakayama Y, Ogata D, Wada S, Tsuruta S, Matsui Y, Okumura M, et al. Treatment of high tumor mutation burden metastatic extramammary Paget disease with an anti-PD-1 antibody. J Dermatol. 2023; 50: e396–e397. 10.1111/1346-8138.16898 CASPubMedWeb of Science®Google Scholar 5Guercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, et al. Treatment of metastatic extramammary Paget disease with combination ipilimumab and nivolumab: a case report. Case Rep Oncol. 2021; 14: 430–438. 10.1159/000514345 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation